Navigation Links
Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16% as CMS Reimbursement Expands
Date:11/16/2009

WALTHAM, Mass., Nov. 16 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, policy changes made by the Center for Medicare and Medicaid Services (CMS) will cause a surge in obstructive sleep apnea (OSA) diagnostic testing and treatment. MRG's new US Market Opportunities for Respiratory and Sleep Management Devices 2010 report finds that increasing reimbursement opportunities for OSA diagnosis and treatment will drive the OSA market to $1.5 billion by 2014.

CMS recognizes that 80% of OSA patients in the US currently remain undiagnosed and is establishing policies to make treatment of OSA symptoms more convenient for patients. Prior to 2009, OSA could only be diagnosed by polysomnography. Reimbursement for therapeutic OSA devices--such as continuous positive airway pressure machines--was only provided if the polysomnography was performed in a facility-based sleep study laboratory. CMS's 2009 Physician Fee Schedule now extends coverage to diagnoses made with home sleep test systems, as long as the provider of the home sleep test device does not also have a financial interest in selling devices used for OSA treatment.

"This change is expected to significantly expand the amount of people getting tested for OSA and receiving treatment," says Ravindra Sharma, Senior Analyst at MRG. "If people can be tested for OSA in the comfort of their own home, they will likely choose that option over an overnight lab stay. Additionally, this change in reimbursement will also result in significant savings for CMS because home sleep tests cost a fraction of in-lab polysomnographies. As a result, demand for therapeutic OSA devices will be very high through 2014."

MRG's new report, US Market Opportunities for Respiratory and Sleep Management Devices 2010, provides critical insight into emerging trends that will fuel market growth for therapeutic OSA devices, ventilators, oxygen therapy, and sleep diagnostic systems through 2014. The report provides a complete breakdown of unit sales, average selling prices, and revenues by device type. Further detail is provided in a thorough examination of trends caused by government policies such as CMS reimbursement. This report includes five-year forecasts, up-to-date market shares, and in-depth qualitative insights.

Webinar

Members of the media are welcome to attend our upcoming webinar on reimbursement in the sleep management device market. This webinar will be held on Wednesday, December 16, 2009 at 11 a.m. U.S. Eastern Time. For more information, please contact Amy Krohn at 416-364-7776 ext. 101 or by email at akrohn@mrg.net.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 ext. 101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com

SOURCE Millennium Research Group


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
5. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
6. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
7. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
8. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
9. Mayo Clinic Studies Find REM Sleep Behavior Disorder is Associated with Other Features of Neurodegenerative Disorders
10. CherryPharm First All-Natural Food to Improve Sleep
11. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago ... off what later became known as the San Francisco "Summer ... ) is unveiling two radical innovations in strategic market research ... This announcement marks the beginning of Northern Light,s "Summer of ... ...
(Date:6/14/2017)... 2017  In 2016, Embodied Labs took ... competition and came away with $25,000 in seed-fund investment. ... Forbes as "entering the life of another" and by ... "empathy to medical professionals in an entirely new dimension." ... a finalist for the Department of Education,s EdSimChallenge, where ...
(Date:6/11/2017)... 10, 2017  Eli Lilly and Company (NYSE: ... 3 studies of galcanezumab, an investigational treatment for the ... on several key secondary endpoints for galcanezumab compared to ... studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today ... in Boston . ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... ... Republicans in the United States Senate on Thursday released their version of ... differs significantly from the American Health Care Act, which the House passed in May, ... will have to take up the Senate version as-is, if it passes. , The ...
(Date:6/25/2017)... ... 25, 2017 , ... CareSet Labs released the Root NPI Graph today at ... new, greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. ... subsequently called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as ...
(Date:6/25/2017)... , ... June 25, 2017 , ... June is Men’s Health Month and ... most common cancer among men in the U.S. and the third most common cause of ... estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
(Date:6/24/2017)... Erie, PA (PRWEB) , ... June 24, 2017 ... ... was held in Erie, PA at the Sheraton Erie Bayfront and Erie Convention ... hands-on evidence based medicine experience, exhibits, a student quiz bowl, award and scholarship ...
(Date:6/24/2017)... ... ... The weather is heating up and the days are getting longer, providing the ... the summer months provide more than warmer temperatures that are perfect for BBQ’s and ... from direct exposure to the sun. When it comes to the security of homes ...
Breaking Medicine News(10 mins):